Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors

Cell Death and Differentiation

Volumn 20, Issue 4, 2013, Pages 567-575

  Montero Melendez, T ^a   Dalli, J ^a   Perretti, M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Annexin A1; Efferocytosis; Genomics; Inflammation; Resolution

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; CYTOKINE; DEPUDECIN; ENTINOSTAT; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; LIPOCORTIN 1; RESVERATROL; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRAIN HEK293; CELL STRAIN MCF 7; DRUG MECHANISM; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANNEXIN A1; APOPTOSIS; BUTYRATES; CELL LINE, TUMOR; CYTOKINES; DATABASES, CHEMICAL; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; MACROPHAGES; MALE; MCF-7 CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHILS; PHAGOCYTOSIS; TRANSCRIPTOME; VALPROIC ACID;

MUS;

EID: 84874946407     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.154     Document Type: Article

References (54)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
2. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140: 871-882.
3. Dransfield I, Rossi AG, Brown SB, Hart SP. Neutrophils: dead or effete? Cell surface phenotype and implications for phagocytic clearance. Cell Death and Differ 2005; 12: 1363-1367.
4. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-788.
5. Hallett JM, Leitch AE, Riley NA, Duffin R, Haslett C, Rossi AG. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 2008; 29: 250-257.
6. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA et al. Cyclindependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12: 1056-1064.
7. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Disc 2004; 3: 401-416.
8. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6: 1191-1197.
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
10. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7: 54-60.
11. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.
12. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011; 3: 96ra76.
13. Lussier YA, Chen JL. The emergence of genome-based drug repositioning. Sci Transl Med 2011; 3: 96ps35.
14. Stumpel DJ, Schneider P, Seslija L, Osaki H, Williams O, Pieters R et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia. Leukemia Research Fund: UK, 2011.
15. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008; 111: 5654-5662.
16. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10: 321-330.
17. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-342.
18. Wen Z, Wang Z, Wang S, Ravula R, Yang L, Xu J et al. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PloS One 2011; 6: e18278.
19. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009; 9: 62-70.
20. Carafa V, Nebbioso A, Altucci L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov 2011; 6: 131-145.
21. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-3931.
22. Suliman BA, Xu D, Williams BR. HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol 2011; 90: 23-32.
23. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
24. Gillespie J, Savic S, Wong C, Hempshall A, Inman M, Emery P et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel HDAC3-selective inhibitor reduces IL-6 production by PBMC of RA patients. Arthritis and Rheum 2011; 64: 418-422.
25. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2011; 71: 424-431.
26. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006; 176: 5015-5022.
27. Cao DJ, Wang ZV, Battiprolu PK, Jiang N, Morales CR, Kong Y et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 4123-4128.
28. McKinsey TA. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011; 17: 434-441.
29. Renshaw D, Montero-Melendez T, Dalli J, Kamal A, Brancaleone V, D'Acquisto F et al. Downstream gene activation of the receptor ALX by the agonist annexin A1. PloS one 2010; 5.
30. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death and Differ 2007; 14: 1443-1456.
31. Petrella A, D'Acunto CW, Rodriquez M, Festa M, Tosco A, Bruno I et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer 2008; 44: 740-749.
32. D'Acunto CW, Fontanella B, Rodriquez M, Taddei M, Parente L, Petrella A. Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1. Cancer Lett 2010; 295: 85-91.
33. Aoyama M, Kotani J, Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 2010; 26: 653-661.
34. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
35. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
36. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008; 68: 5478-5486.
37. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 2995-3000.
38. Solito E, Kamal A, Russo-Marie F, Buckingham JC, Marullo S, Perretti M. A novel calciumdependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 2003; 17: 1544-1546.
39. Yona S, Heinsbroek SE, Peiser L, Gordon S, Perretti M, Flower RJ. Impaired phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol 2006; 148: 469-477.
40. Scannell M, Flanagan MB, deStefani A, Wynne KJ, Cagney G, Godson C et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 2007; 178: 4595-4605.
41. Blume KE, Soeroes S, Waibel M, Keppeler H, Wesselborg S, Herrmann M et al. Cell surface externalization of annexin A1 as a failsafe mechanism preventing inflammatory responses during secondary necrosis. J Immunol 2009; 183: 8138-8147.
42. Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications in health and disease. J Cell Biol 2010; 189: 1059-1070.
43. Serhan CN. The resolution of inflammation: the devil in the flask and in the details.. FASEB J 2011; 25: 1441-1448.
44. Brancaleone V, Dalli J, Bena S, Flower RJ, Cirino G, Perretti M. Evidence for an antiinflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol 2011; 186: 4905-4914.
45. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 2006; 107: 2123-2130.
46. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptidestimulated phagocytosis. FASEB J 2010; 24: 4240-4249.
47. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345-4355.
48. Damazo AS, Yona S, Flower RJ, Perretti M, Oliani SM. Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol 2006; 176: 4410-4418.
49. Schwab JM, Chiang N, Arita M, Serhan CN. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-874.
50. Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Aktdependent and NF-kappaB-independent manner. J Leukoc Biol 2010; 87: 895-904.
51. Vago JP, Nogueira CR, Tavares LP, Soriani FM, Lopes F, Russo RC et al. Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis. J Leukoc Biol 2012; 92: 249-258.
52. Pupjalis D, Goetsch J, Kottas DJ, Gerke V, Rescher U. Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling. EMBO Mol Med 2011; 3: 102-114.
53. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis and cartilage/OARS. Osteoarthritis Cartilage 2008; 16: 723-732.
54. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J 2003; 17: 253-255.